Press releasePRNewswire
Elicio Therapeutics
ELTX · NASDAQ
$1.57+$0.02 (+1.29%)TodayMarket closed ·
Prev close $1.55
Latest news
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
- NewsAvi Kapoor
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsVandana Singh
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
- Press releasePRNewswire
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
- NewsVandana Singh
Elicio Therapeutics Pancreatic Cancer Study Disappoints
- Press releaseGlobe Newswire
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
- NewsAvi Kapoor
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
- NewsAvi Kapoor
Dow Jumps Over 600 Points Following US-Iran Peace Deal
- Press releaseGlobe Newswire
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
- Press releaseGlobe Newswire
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
- Press releaseGlobe Newswire
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
- News
Elicio's Pancreatic Cancer Vaccine Trial Clears Key Review, Moves Ahead Without Changes
- Press releaseGlobe Newswire
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
- NewsAvi Kapoor
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.